Oncology Intelligence Platform

Rescued
Oncology
Assets

We don't discover new drugs.
We find the right context for drugs the market abandoned too soon.

Rescued Oncology Assets are clinically de-risked compounds with intact biological rationale, discontinued due to suboptimal patient context, inadequate TME conditions, or missing synthetic lethality pairing — not due to intrinsic molecular failure.
Start Free Pilot Our Approach
FDO
TD · BM
HD
20,121 Records Analyzed
1,884 Cross-Domain Connections
91.6 Avg Dataset Score
~4,000 Shelved Compounds Mapped
5–10d Report Delivery
The Problem

90% of oncology drugs fail.
But failure is not the molecule's fault.

Three structural reasons explain most clinical failures — none of them invalidate the underlying biology.

👤
Wrong Patient
Unselected populations dilute the signal. A drug that works in 15% of patients fails the trial — but those 15% were never identified. The biomarker was never defined.
🧱
Hostile Microenvironment
Rigid ECM. Elevated interstitial pressure. Dense desmoplasia. The drug never reaches its target. The TME blocks delivery before pharmacology can act.
🔗
Missing Partner
The molecule alone is insufficient. It needed a synthetic lethality partner — a second hit targeting a co-vulnerability the trial design never considered.
~4,000
compounds with solid biological rationale were discontinued before finding the right context.
They are not failed drugs. They are context-orphan assets waiting for the right framework.
Our Approach

The Logikron Triad

Three levers. One sequence. One operational protocol that transforms shelved compounds into trial-ready hypotheses.

01 — SYNTHETIC LETHALITY
The Second Hit
We identify synthetic lethality pairs where the asset becomes the second hit in a genomically-driven combination. Two individually tolerable vulnerabilities — lethal together in tumor cells, spared in normal tissue.
02 — TME RESTORATION
The Right Terrain
Using our FDO·TD·BM·HD system, we quantify TME hostility through the proprietary κ parameter. We design normalization strategies that restore drug penetration above the critical threshold before the asset is applied.
03 — SUBCOHORT SELECTION
The Right Patient
We define the predictive biomarker signature that identifies the responding subcohort. Statistical failure becomes clinical success when the population is correctly stratified by genomic, mechanical and immunological profile.
Sequence → Select the patient → Normalize the TME → Apply synthetic lethality
Proprietary System

FDO · TD · BM · HD

Four integrated physical models generate the κ parameter — Logikron's proprietary index of TME pharmacological accessibility.

FDO
Deformable Object Physics
ECM deformation modeling under mechanical stress. Quantifies matrix stiffness and its impact on drug diffusion pathways.
κ = f(E, ν, σ)
TD
Biological Thermodynamics
Energy gradient analysis within the tumor microenvironment. Local entropy and thermal flux as pharmacological accessibility predictors.
ΔG = ΔH − TΔS
BM
Cellular Biomechanics
Traction forces, nuclear stiffness and mechanosensory transduction. Maps the mechanical state of the tumor cell and its microenvironment.
F = k · δ
HD
Interstitial Hydrodynamics
Interstitial pressure, lymphatic flow and pharmacological penetration barriers. Critical for predicting actual drug delivery at the tumor site.
Q = −κ∇P
⬡ The integration of all four modules generates the κ parameter — Logikron's proprietary index of TME pharmacological accessibility. Critical threshold identified at κ < 19.5 kPa. Validated on OMIKRON V14 dataset. Full methodology is proprietary.
The Pipeline

From Shelved to Trial-Ready

Five steps. One deliverable. A complete action thesis ready for clinical translation.

01
Asset Scan
Compounds with solid preclinical rationale and disappointing clinical outcomes. Sources: ClinicalTrials · ChEMBL · DrugBank · OMIKRON V14
02
Cross-Domain Analysis
OMIKRON V14 database. 20,121 records. 1,884 cross-domain connections. Avg score 91.6. Multi-layer biological signal extraction.
03
FDO·TD·BM·HD
Proprietary system. κ parameter computation. TME accessibility assessment. Normalization strategy design. [Methodology reserved]
04
SL Mapping
Synthetic lethality partners identified. Biomarker-driven pairing. Genomic co-vulnerability validation. Priority pair shortlist generated.
05
Report & Thesis
Trial-ready action thesis. Delivered in 5–10 business days. Includes regulatory rationale, biomarker strategy and subcohort definition.
OUTPUT · Drug candidate · SL partner · TME strategy · Predictive biomarkers · Subcohort definition · Regulatory rationale
Science

Synthetic Lethality Pairing

Two vulnerabilities tolerable in isolation. Lethal when combined — selectively in tumor cells carrying the target mutation.

Normal Cell
Gene A  ✓ intact
Gene B  ✓ intact

SL drug applied
→ Survives
≠
Selective
lethality
Tumor Cell
Gene A  ✗ mutated
Gene B  ✓ intact

SL drug applied
→ Cell Death

Priority SL pairs identified by OMIKRON V14:

BRCA1/2 × PARP
Founding paradigm — clinically validated
ATM × ATR/CHK1
DDR pathway — high Logikron priority
WRN × MSI-H
Microsatellite instability — emerging target
ARID1A × EZH2
SWI/SNF alterations — selective response
TME Restoration

The right drug fails in the wrong terrain.

We normalize the tumor microenvironment before applying the asset — turning a pharmacological barrier into a delivery window.

✗ Hostile TME — Before
✗ Rigid ECM — κ above critical threshold
✗ Elevated interstitial pressure
✗ Marked desmoplasia
✗ Local immunosuppression
✗ Drug penetration < 20%
✗ Hypoxia — intrinsic resistance
→
κ
normalized
✓ Normalized TME — After
✓ Normalized ECM — κ < 19.5 kPa
✓ Reduced interstitial pressure
✓ Attenuated desmoplasia (LOX-inh.)
✓ Restored immunosurveillance
✓ Drug penetration > 70%
✓ Improved oxygenation
κ < 19.5 kPa
Logikron critical threshold — below this value, pharmacological penetration exceeds 70% and the Rescued Oncology Asset can be effectively applied.
Validated on OMIKRON V14 dataset · FDO·BM·HD integrated methodology.
Start Now

Start with a
Free Pilot

Send us the name of a drug or a clinical program.
You'll receive a first assessment within 5 business days.
No commitment. No contract. Just results.

✉
Email
info@logikron.org
🌐
Web
www.logikron.com
📍
Company
KRONOMED SRL · Italy
Send Your Compound →

OMIKRON V14 · 20,121 records · 1,884 cross-domain connections · Delivery in 5–10 days
For research use only · KRONOMED SRL · Confidential